ストックスクリーナーアプリを入手
3.37
4.33%
0.14
前日終値:
$3.23
開ける：
$3.4199
24時間の取引高:
44,554
Relative Volume:
0.80
時価総額：
$338.99M
収益：
$73.01M
当期純損益:
$-67.89M
株価収益率:
-4.9771
EPS:
-0.6771
ネットキャッシュフロー:
$-43.68M
1週間 パフォーマンス:
-2.88%
1か月 パフォーマンス:
-19.38%
6か月 パフォーマンス:
+1.51%
1年 パフォーマンス:
+157.25%
1日の値動き範囲:
$3.24
$3.42
1週間の範囲:
$3.19
$3.49
52週間の値動き範囲:
$1.10
$5.4796
Cellectis Adr Stock (CLLS) Company Profile
Compare CLLS vs VRTX, REGN, ALNY, ARGX, INSM
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CLLS
Cellectis Adr
|
3.37 | 338.99M | 73.01M | -67.89M | -43.68M | -0.6771 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Cellectis Adr Stock (CLLS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-17 | 再開されました | Jefferies | Buy |
| 2023-03-17 | 開始されました | Bryan Garnier | Buy |
| 2022-05-18 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2022-01-06 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2021-11-30 | 開始されました | JMP Securities | Mkt Outperform |
| 2021-11-08 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2021-10-08 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2021-04-28 | ダウングレード | Guggenheim | Buy → Neutral |
| 2021-03-16 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2020-08-19 | アップグレード | Citigroup | Neutral → Buy |
| 2020-05-12 | 開始されました | Robert W. Baird | Outperform |
| 2020-03-06 | ダウングレード | Goldman | Neutral → Sell |
| 2019-10-30 | 再開されました | Guggenheim | Buy |
| 2019-08-09 | 開始されました | BTIG Research | Buy |
| 2019-05-24 | 再開されました | Citigroup | Neutral |
| 2019-03-14 | 開始されました | William Blair | Outperform |
| 2018-12-19 | 開始されました | Goldman | Neutral |
| 2018-07-16 | 開始されました | Barclays | Overweight |
| 2018-03-16 | 開始されました | Guggenheim | Neutral |
| 2017-09-05 | ダウングレード | SunTrust | Buy → Hold |
| 2017-09-05 | 繰り返されました | Wells Fargo | Outperform |
| 2017-03-02 | 開始されました | Instinet | Buy |
| 2017-02-28 | 開始されました | Wells Fargo | Outperform |
| 2016-04-05 | 開始されました | Ladenburg Thalmann | Buy |
| 2016-03-02 | 開始されました | Sun Trust Rbsn Humphrey | Buy |
| 2015-07-20 | 開始されました | BofA/Merrill | Buy |
| 2015-04-20 | 開始されました | Jefferies | Buy |
| 2015-04-20 | 開始されました | Piper Jaffray | Overweight |
すべてを表示
Cellectis Adr (CLLS) 最新ニュース
Cellectis earnings beat by $0.10, revenue topped estimates - Investing.com
Cellectis (NASDAQ: CLLS) 2025 annual report shows losses and funding runway - Stock Titan
Cellectis Reports Full Year 2025 Financial Results and Provides a Business Update - ChartMill
Cellectis to Report Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026 - ChartMill
European ADRs Slipped As Biopharma Dragged The Pack - Finimize
European ADRs Rose In US Trading, Led By HSBC And Sequans - Finimize
European ADRs Slipped To Start The Week, With Pharma Leading Moves - Finimize
Jefferies assumes coverage on Cellectis stock with Buy rating - Investing.com
European ADRs Started The Week Higher In US Trading - Finimize
ETFs Investing in Cellectis S.A. Sponsored ADR Stocks - TradingView — Track All Markets
Traders are paying attention to the gapping stocks in Monday's session. - ChartMill
Clear Street initiates Cellectis stock with Buy rating on CAR-T potential - Investing.com
Working capital per share of Cellectis S.A. Sponsored ADR – NASDAQ:CLLS - TradingView — Track All Markets
European ADRs Inch Up As 3D Printer Materialise Leads Gains - Finimize
Allogene Arbitration Victory Pressures Cellectis Shares Tuesday - Benzinga
Lightwave Logic, Kyverna Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Sahm
Allogene Arbitration Victory Pressures Cellectis Shares Tuesday - Sahm
Arbitration ruling partially terminates Cellectis-Servier license agreement - Investing.com
European ADRs Stay Put As Novo Nordisk Slides - Finimize
12 Health Care Stocks Moving In Monday's Pre-Market Session - Sahm
Moligo and Cellectis show promise in non-viral gene editing method - Investing.com India
Moligo Technologies and Cellectis Demonstrate Potential of Enzymatic Single-Stranded DNA for Non-Viral Gene Editing in Nature Communications - Sahm
Cellectis reports breakthrough in non-viral gene editing technique - Investing.com
Citizens maintains Cellectis stock rating with $8 target ahead of ASH update - Investing.com
European ADRs Slip As Gains And Losses Balance Out - Finimize
Cellectis to Present a Development Update for eti-cel at ASH 2025 - Chartmill
European ADRs Dip As Biotech Stocks Tumble In US Trading - Finimize
Olema Pharmaceuticals, Exelixis, Genmab And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
Cellectis Adr (CLLS) 財務データ
収益
当期純利益
現金流量
EPS
1.82%
大文字化:
|
ボリューム (24 時間):